Rchr
J-GLOBAL ID:201501006753217368   Update date: Jun. 21, 2024

Boku Shuken

ボク シュウケン | Boku Shuken
Affiliation and department:
Job title: 准教授
Research field  (1): Psychiatry
Research theme for competitive and other funds  (13):
  • 2023 - 2027 Stratification of depression based on lysophospholipid metabolic disorders and innovative development of novel antidepressants
  • 2022 - 2025 海馬アストロサイトに着目した電気けいれん療法の作用機序解明
  • 2020 - 2022 間歇型一酸化炭素中毒の病態解明及び治療の究明
  • 2019 - 2022 Reserach of depression focusing on D-amino acids
  • 2018 - 2021 幼少期ストレスとmiRNAに着目した気分障害の診断と治療に直結する病態解明研究
Show all
Papers (121):
  • Akihiro Takasaki, Mamoru Hashimoto, Ryuji Fukuhara, Shizuka Sakuta, Asuka Koyama, Tomohisa Ishikawa, Shuken Boku, Manabu Ikeda, Minoru Takebayashi. Gesture imitation performance in community-dwelling older people: assessment of a gesture imitation task in the screening and diagnosis of mild cognitive impairment and dementia. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2024. 24. 2. 404-414
  • Kotaro Miyako, Naoto Kajitani, Yusaku Koga, Hitoshi Takizawa, Shuken Boku, Minoru Takebayashi. Identification of the antidepressant effect of electroconvulsive stimulation-related genes in hippocampal astrocyte. Journal of Psychiatric Research. 2024. 170. 318-327
  • Yusaku Koga, Naoto Kajitani, Kotaro Miyako, Hitoshi Takizawa, Shuken Boku, Minoru Takebayashi. TCF7L2: A potential key regulator of antidepressant effects on hippocampal astrocytes in depression model mice. Journal of Psychiatric Research. 2024. 170. 375-386
  • 本田 和揮, 都 剛太朗, 藤瀬 昇, 朴 秀賢, 竹林 実. 【焦燥が強い病態とその治療】レビー小体型認知症と焦燥. Dementia Japan. 2024. 38. 1. 57-63
  • Toshinori Chiba, Kentarou Ide, Misa Murakami, Nao Kobayashi, Taiki Oka, Fumiya Nakai, Rumi Yorizawa, Yuka Miyake, Toshitaka Hamamura, Masaru Honjo, et al. Event-related PTSD symptoms as a high-risk factor for suicide: longitudinal observational study. Nature Mental Health. 2023. 1. 12. 1013-1022
more...
MISC (41):
  • 吉浦和宏, 福原竜治, 石川智久, 石川智久, 小山明日香, 津野田尚子, 津野田尚子, 宮川雄介, 日高洋介, 梶谷直人, et al. 認知的フレイルの臨床的特徴を考慮した認知症予防策の検討:熊本県荒尾市における認知症コホート研究(JPSC-AD). 日本社会精神医学会プログラム・抄録集. 2024. 42nd
  • 本田和揮, 都剛太朗, 藤瀬昇, 朴秀賢, 竹林実. Dementia with Lewy bodies and agitation. Dementia Japan. 2024. 38. 1
  • 梶谷直人, 梶谷直人, 梶谷直人, 岡田麻美, 井上飛鳥, 朴秀賢, 青木淳賢, 竹林実, 竹林実. Tricyclic antidepressants act as a G protein-biased LPA1 receptor agonist and contribute to antidepressant effects. 日本生物学的精神医学会(Web). 2023. 45th
  • 三角雅裕, 増田一樹, 宮川雄介, 田中響, 福原竜治, 朴秀賢, 竹林実, 竹林実. A case of treatment-refractory and drug-intolerant depression in the elderly suspected the involvement of Lewy body disease and successfully treated with ECT. 精神科治療学. 2023. 38. 9
  • 新井脩泰, 佐藤英明, 高島諒, 宮川雄介, 今井智之, 朴秀賢, 竹林実, 竹林実. ECT開始後のクロザピン導入と維持ECTとの併用で寛解した治療抵抗性統合失調症の一例. 総合病院精神医学. 2023. 35. Supplement (Nov)
more...
Books (1):
  • Depression Frontier 2 うつ病臨床のこんな疑問に答えるー脳科学からのアプローチ / うつ病は脳の問題ですよね? 詳しく教えて下さいー神経細胞新生とうつ病
    医薬ジャーナル社 2016
Lectures and oral presentations  (42):
  • Electric stimulation increases expression of leukemia inhibitory factor in astrocytes via adenosine triphosphate receptor P2X2
    (ACNP 2018 2018)
  • The cell cycle-related genes as biomarkers for schizophrenia
    (Neuroscience 2018 Annual Meeting 2018)
  • Mosaic loss of chromosome Y in peripheral blood and its risk variants in men with schizophrenia
    (WFSBP Asia Pacific Regional Congress of Biological Psychiatry 2018 KOBE 2018)
  • Mitochondrial DNA copy number of peripheral blood in bipolar disorder:the present study and a meta-analysis
    (WFSBP Asia Pacific Regional Congress of Biological Psychiatry 2018 KOBE 2018)
  • Increased serum levels and promoter polymorphisms of macrophage migration inhibitory factor in schizophrenia
    (WFSBP Asia Pacific Regional Congress of Biological Psychiatry 2018 KOBE 2018)
more...
Education (2):
  • 1998 - 2002 Kyoto University Graduate School of Medicine
  • 1992 - 1998 Kyoto University Faculty of Medicine
Professional career (1):
  • 博士(医学) (北海道大学)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page